February 26, 2013 4:17 PM | 29 seconds read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimallydisruptive surgical products and procedures for the spine, is proudto announce that the very first eXtreme Lateral Interbody Fusion(XLIF(R)) procedures were performed yesterday and today at twodifferent hospitals in Japan. NuVasive has received regulatory Shonin approval for several productsto offer the XLIF surgical technique as a minimally invasive optionfor lumbar spine fusion to patients and surgeons in Japan. Theapproval furthers the Company's ability to participate in theJapanese market, adding the XLIF approach to the cervical andposterior products that were approved for use late last year.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.